Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses

Published:2013-01 Issue:1 Volume:21 Page:91-100
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Yang Xuanming,Zhang Xunmin,Mortenson Eric D,Radkevich-Brown Olga,Wang Yang,Fu Yang-Xin

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference34 articles.

1. EGF-ERBB signalling: towards the systems level;Citri;Nat Rev Mol Cell Biol,2006

2. ErbB-targeted therapeutic approaches in human cancer;Arteaga;Exp Cell Res,2003

3. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor;Chen;Nature,1987

4. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

5. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study;Nature Communications;2024-08-23

2. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy;Scientific Reports;2024-01-20

3. Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study;Frontiers in Oncology;2024-01-16

4. The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma;Journal of Cancer;2024

5. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC;Cancer Research Communications;2023-10-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3